Hematologic malignancies are cancer which instigate in the cells of blood-forming tissue like the bone marrow, or in the cells of the immune system. The cancer can be treated with different therapies like radiotherapy, stem cell transplantation, chemotherapy, and immunotherapy.
Innovative Drugs to Treat Different Types of Cancers
Hematologic malignancies are categorized into lymphoma, multiple myeloma, and leukemia. Leukemia is further classified into chronic lymphocytic, acute lymphocytic, chronic myeloid leukemia, and acute myeloid. In 2016, Leukemia was estimated for largest segment due to the presence of popular brands like Imbruvica, Glivec, and Rituxan which are reported to be some of the main revenue generating oncology drugs.
Acute lymphocytic leukemia is most communally occurring type of leukemia, which was estimated for 56% of cases in youths and 80% in kids during 2016 to 2017. For instance, On November 1, 2017, Pfizer Inc. and Cellectis declared the initial results of two phase 1 trials for UCART19 CAR T-cell product. This data presented during American Society of Hematology (ASH) annual summit and exposition. The CALM study, an open label, dose expansion study planned to evaluate tolerability, antileukemic activity, and safety of UCART19 in patients with reverted or refractory CD19-positive B-cell acute lymphoblastic leukemia.
Acute myeloid is likely to witness the fastest growth during the forecast period. This growth can be associated with the presence of a strong product pipeline and their expected commercialization.
Market Overview
According to Grand View Research, Inc., the worldwide hematologic malignancies market is predicted to achieve USD 85.8 billion by 2025. Factors such as increasing alliances between various government organizations and research institutes across the world for evolving innovative therapies, growing government backing, rising awareness among patients and healthcare authorities can propel the market during the forecast period (2014 to 2025).
In 2016, North America lead the market and acquired share over 39% due to the presence of top companies and technologically advanced healthcare infrastructure. Asia Pacific is expected to be the fastest growing market during the forecast period with CAGR of 12.5% due to growing expenses for the development of healthcare infrastructure and availability of effective treatment.
Some of the leading companies operating in the market include GlaxoSmithKline PLC; Pfizer, Inc.; Johnson & Johnson Services, Inc.; Hoffmann-LA Roche ltd; and Bristol-Myers Squibb Company.
In-Depth Research Report On Hematologic Malignancies Market:
https://www.grandviewresearch.com/industry-analysis/hematologic-malignancies-market
No comments:
Post a Comment